Streetbeat News

ESLA

Estrella Immunopharma, Inc.

https://www.estrellabio.com

Industry

Biotechnology

Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.

Open

0.89

Mkt cap

32M

Volume

22K

High

0.93

P/E Ratio

-3.71

52-wk high

3.23

Low

0.89

Div yield

N/A

52-wk low

0.63

The article reports on the after-market movements of several healthcare stocks. Notable gainers include Tenon Medical, Alphatec Holdings, and Envista Holdings, while Corcept Therapeutics and Acadia Healthcare Co are among the losers, influenced by their Q3 earnings reports.

Portfolio Pulse from Benzinga Insights

October 30, 2024 | 8:31 pm

In Monday's pre-market session, several healthcare stocks experienced significant movements. Prime Medicine, Traws Pharma, and Tharimmune saw notable gains, while Ensysce Biosciences and Corvus Pharma faced declines. Earnings reports influenced some stock movements.

Portfolio Pulse from Benzinga Insights

September 30, 2024 | 12:06 pm

Several healthcare stocks experienced significant price movements in Friday's after-market session. Notable gainers included IGC Pharma, TC BioPharm, and OptiNose, while Gain Therapeutics, Estrella Immunopharma, and Eyenovia were among the losers.

Portfolio Pulse from Benzinga Insights

September 27, 2024 | 8:31 pm

Estrella Immunopharma's shares rose after announcing a complete response in the first patient of its STARLIGHT-1 Phase I/II trial using EB103 CD19-Redirected ARTEMIS T Cells.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2024 | 6:20 pm

Estrella Immunopharma's shares are trading lower despite announcing a complete response from its first patient treated with Cd19-redirected artemis t-cells.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2024 | 4:39 pm

Several health care stocks experienced significant price movements during Friday's intraday session. Onconetix, Cue Biopharma, Plus Therapeutics, Estrella Immunopharma, Indaptus Therapeutics, and Mainz Biomed saw notable gains, while Theriva Biologics, enVVeno Medical, Inspire Veterinary, Palatin Techs, Acadia Healthcare, and Impact BioMedical experienced declines.

Portfolio Pulse from Benzinga Insights

September 27, 2024 | 4:31 pm

Estrella Immunopharma has achieved a complete response in the first patient treated with their CD19-redirected Artemis T-cells, marking a significant milestone in their clinical trials.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2024 | 4:01 pm

Estrella Immunopharma has appointed Hong Zhang as Chairperson and Board Member, expanding its board from five to six directors. This follows the dosing of the first patient in its Phase I/II clinical trial for EB103 T-Cell Therapy. CEO Dr. Cheng Liu will continue as a director.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2024 | 4:01 pm

In Tuesday's after-market session, several healthcare stocks showed notable movements. Apollomics, Cara Therapeutics, Coeptis Therapeutics, Titan Pharma, BioSig Technologies, and Iridex were among the gainers, with increases ranging from 5.52% to 10.9%. On the downside, Akili, Mira Pharmaceuticals, Estrella Immunopharma, Virpax Pharmaceuticals, United Therapeutics, and ProSomnus experienced declines between 6.46% and 22.9%. Iridex and ProSomnus also released their Q4 earnings.

Portfolio Pulse from Benzinga Insights

March 26, 2024 | 9:32 pm

In Friday's after-market session, several healthcare stocks showed notable movements. Talphera's shares surged by 15.6% following its Q4 earnings report. Other gainers included Genelux, Estrella Immunopharma, Inspire Veterinary, NRX Pharmaceuticals, and Fortrea Holdings with increases ranging from 5.02% to 10.06%. Conversely, Atara Biotherapeutics led the losers, dropping by 9.4%, followed by declines in ProKidney, Mira Pharmaceuticals, Yield10 Bioscience, GeneDx Hldgs, and Envoy Medical.

Portfolio Pulse from Benzinga Insights

March 08, 2024 | 9:31 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.